• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

    27.59 -0.51 (-1.81%)
    Streaming Delayed Price Updated: 1:23 PM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 425,195
    Open 28.19
    Bid (Size) 27.58 (100)
    Ask (Size) 27.61 (100)
    Prev. Close 28.10
    Today's Range 27.20 - 28.30
    52wk Range 9.900 - 34.29
    Shares Outstanding 9,587,155
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Prepares for Transformational 2026
    From Viridian Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -10.1%
    -10.1%
    1 Month
    -15.5%
    -15.5%
    3 Month
    -6.4%
    -6.4%
    6 Month
    +53.1%
    +53.1%
    1 Year
    +66.4%
    +66.4%

    More News

    Read More
    News headline image
    Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Inc (NASDAQ:VRDN) Shows High-Growth Momentum and Strong Technical Setup ↗
    Via Chartmill
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Proposed Underwritten Public Offering
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts ↗
    Via Benzinga
    News headline image
    Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    Via Benzinga
    News headline image
    Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results ↗
    Via Benzinga
    News headline image
    Viridian (VRDN) Q2 Net Loss Widens 55% ↗
    Via The Motley Fool
    News headline image
    Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
    From Viridian Therapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
    Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
    The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
    What is the current price of Viridian Therapeutics, Inc. - Common Stock?
    The current price of Viridian Therapeutics, Inc. - Common Stock is 27.59
    When was Viridian Therapeutics, Inc. - Common Stock last traded?
    The last trade of Viridian Therapeutics, Inc. - Common Stock was at 02/20/26 01:23 PM ET
    What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
    The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 264.51M
    How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
    Viridian Therapeutics, Inc. - Common Stock has 265M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.